THE TALK: Breast Cancer - Episode 3
Updates in HR+/HER2- Breast Cancer: The MONALEESA-2 Trial
Breast oncologists explain results from the phase III MONALEESA-2 trial presented at ESMO 2021, and its clinical implications.
Data from the following clinical trial are discussed:
- LBA17_PR - Overall survival (OS) results from the phase 3 MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)
Related Content:
